Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | UBE2N | P61088 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23233860 | 0.89 | BRD4 (0.46) | BRD4L3MBTL1GAAHTR6 | |
| SCHEMBL27214855 | 0.88 | BRD4 (0.45) | BRD4HTR6 | |
| SCHEMBL27214871 | 0.85 | BRD4 (0.52) | BRD4L3MBTL1ALOX5PTGS2KDM4E | |
| SCHEMBL17748988 | 0.84 | BRD4 (0.53) | BRD4L3MBTL1ALOX5PTGS2HTR6 | |
| SCHEMBL27214878 | 0.83 | BRD4 (0.45) | BRD4L3MBTL1ALOX5PTGS2KDM4E | |
| SCHEMBL31134032 | 0.80 | BRD4 (0.40) | BRD4L3MBTL1KDM4E | |
| SCHEMBL17753721 | 0.79 | BRD4 (0.50) | BRD4ALOX5PTGS2KDM4EGAA | |
| SCHEMBL27438221 | 0.79 | BRD4 (0.56) | BRD4L3MBTL1KDM4EUBE2NHTR6 | |
| SCHEMBL23212213 | 0.77 | BRD4 (0.49) | BRD4L3MBTL1ALOX5PTGS2KDM4E | |
| SCHEMBL23212220 | 0.77 | BRD4 (0.50) | BRD4L3MBTL1KDM4EUBE2NHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114401964-B | Compound with BRD4 inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240150343-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| EP-4043462-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2022-08-17 | — | — | EP | disclosed |
| CN-114401964-A | Compound with BRD4 inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2021068755-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2021-04-15 | — | — | WO | disclosed |
| CN-112625036-A | Compound with BRD4 inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150343-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | BRD4, BICRA, BET1 | BRD4 1/4885L3MBTL1 1285/4885ALOX5 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.